Market news

Oscar Health (OSCR) has drawn fresh attention after management highlighted a roadmap to higher earnings per share, tied to medical loss ratio discipline and new offerings such as the Lucy Healthcare Marketplace and AI powered tools. Recent trading has been choppy for Oscar Health, with the share price slipping 5.40% over seven days and 2.86% over 30 days. However, a 3.79% 90 day share price return and a 97.73% year to date share price return suggest momentum has been building over a longer...

Oscar Health has been on a powerful run in recent years, yet the real question for you today is whether the current share price lines up with what its earnings story can reasonably support. The stock has also seen shorter term pullbacks, which makes the earnings backdrop even more important for anyone trying to judge what they are actually paying for. Over the past 3 years the stock has delivered a very large gain of about 4.3x, which puts a lot of weight on whether the underlying earnings...

Oscar Health (OSCR) buy thesis: $45–$49 fair value on ACA growth, improving margins and Lucie upside.

Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.

Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oscar Health's addressable population could rise to ~16 million by 2029, which is a 65% expanded TAM. Read why OSCR stock is upgraded to a strong buy.

Oscar Health, Inc. (OSCR) closed the most recent trading day at $31.29, moving 2.61% from the previous trading session.

Oscar Health (NYSE:OSCR) used its Investor Day to unveil the Lucy Healthcare Marketplace, an AI-driven platform for carriers, brokers, and consumers. Management outlined a plan to double earnings per share by 2027, describing it as a core pillar of Oscar Health's next phase. CEO statements at the event argued that traditional employer-sponsored health insurance is ending, and Oscar Health aims to focus on individual coverage. The Lucy Healthcare Marketplace launch and Oscar Health's shift...

Oscar Health (OSCR) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Oscar Health's (OSCR) target of reaching over $4 of earnings per share by 2029 is "predicated on fai

Oscar Health cut its medical cost outlook, lifting OSCR stock. The insurer's grab for share in a shrinking ACA market looks like a winner — for now.

Oscar Health, Inc. (OSCR) closed at $32.62 in the latest trading session, marking a -3.53% move from the prior day.

Here is how Oscar Health, Inc. (OSCR) and Amerant Bancorp Inc. (AMTB) have performed compared to their sector so far this year.

A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.

Detailed price information for Oscar Health Inc Cl A (OSCR-N) from The Globe and Mail including charting and trades.

Here's why Oscar Health may be hardest hit from CVS' comments.

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Oscar Health's membership jumps 46% to 2.96 million, but seasonal enrollment and medical utilization keep profitability in focus.

Oscar Health has surged 109% YTD as membership, revenue and expansion plans strengthen, though its price-to-book multiple tops the industry average.

Oscar Health stock has delivered very strong 3 year gains, yet the broad valuation checks currently lean expensive and do not clearly support it as a bargain. After such a sharp move, investors are trying to work out whether the recent share price now runs ahead of the fundamentals or is still justified by the company’s prospects. Oscar Health has returned about 3.6x over 3 years, which puts extra focus on whether recent gains already reflect much of the potential that investors see in the...

Oscar Health (OSCR) recently reported record first half 2026 results and raised its full year guidance, a combination that appears to have supported renewed investor attention on the stock this month. At a share price of US$30.47, Oscar Health has seen some short term volatility, with a 7 day share price return down 4.9%. However, the 90 day share price return of 37.07% and 3 year total shareholder return of 363.07% suggest momentum has been strong over a longer stretch as investors react to...

Earlier in 2026, Oscar Health reported record first-half financial results and lifted its full-year guidance, prompting analysts to raise their earnings estimates and highlight a low PEG ratio of 0.6 as evidence of relatively modest valuation expectations. This combination of upgraded guidance and analyst estimate revisions underscores how improving profitability expectations are reshaping perceptions of Oscar Health’s earnings power and growth profile. We’ll now examine how Oscar Health’s...

Oscar Health (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Efficiency improvements are boosting profit margins for Oscar Health.

Motley Fool Press Release.

Oscar Health CEO Mark Bertolini identified uncovered GLP-1 drugs as a potential use case for Hims on the marketplace.

Oscar Health (OSCR) is back in focus after reporting second quarter 2026 results that swung from a loss to net income of $361.81 million and raising full year earnings guidance. See our latest analysis for Oscar Health. Oscar Health shares have been volatile around the earnings release, with an 11.9% drop reported after the outlook update. The stock still shows a 118.84% year to date share price return and a 109.46% 1 year total shareholder return, suggesting momentum remains strong despite...

Oscar Health stock has delivered a very large 3 year return while the broader valuation checks still lean cautious, with a low value score hinting that the recent re rating may not be a simple bargain story. Oscar Health has returned about 3.6x over the past 3 years, which puts a spotlight on whether recent enthusiasm already prices in much of the progress. Recent profitability and revenue growth can support investor expectations for the business, while concerns around medical cost trends...

Oscar Health’s second quarter saw results well above Wall Street’s expectations, yet the market response was notably negative. Management credited disciplined pricing, technology-driven cost efficiencies, and strong execution in the individual health insurance market for driving year-over-year revenue and margin improvement. CEO Mark Bertolini highlighted that “disciplined pricing, differentiated consumer products and a scalable technology platform” fueled growth, with membership up 46% and admi

Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net income of $361.8 million from a $228.4 million loss. The stock […]

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Oscar Health (NYSE:OSCR) and its peers.

Detailed price information for Oscar Health Inc Cl A (OSCR-N) from The Globe and Mail including charting and trades.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Q2 Earnings Roundup: Oscar Health (NYSE:OSCR) And The Rest Of The Health Insurance Providers Segment

Oscar Health (NYSE:OSCR) reported record profitability for the first half of 2026 and raised its full-year operating outlook, citing membership growth, disciplined pricing, favorable utilization trends and lower administrative expense ratios. Chief Executive Officer Mark Bertolini said the company